Not bagholden
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The tweet said “interim” on the tweet.
F that guy…. He is a disgrace, and embarrassing
Beautiful post should be stickied.
They are all connected. Who is gonna be the new CEO??
Huh? Seems to be churning at 10 month highs. She looks damn good.
We haven’t even heard any of the story yet.
Finally waking up...
Sure ya did. ;)
Sure is looking damn good
You have been holding a bag here for months... LOL
Ouch… bad weekly with owners rinsing the ignorant at the top.
I’m just in for a trade…
Might be making a turn here
Much better now...
They need to start talking. Hopefully soon.
No secret there is/was a crap ton of dilution.
The idea is, now that it is slowing or coming to an end it will move back up.
Showing your ignorance once again are we?
Florida SOS has been updated, OTC is going through the normal/standard verification process with the new team.
I know it’s hard to let go of 15 years of “work”, but open yer eyes bud…
I never said it wasn’t. You said you have never seen such a small float in trips…
Which is obviously very wrong. So I pointed you to one.
$350k in cash flow today with a VWAP of .022
Wow. You have been holding this bag for a damn long time. January 19th 2022 the PPS was .0045.
MONI another high hit today. Is this the 3rd time you warned us about “the top”?
Looks like a possibly trade opportunity..
Yeah. Good story is what helped them dump over 700 million shares. But it moved and made people money.
The smart ones that actually traded it anyway
Notes just about done selling. So traders are pushing it up. Nice opportunity for a trade.
That’s another one that diluted down to the trips. It had a 350 million float in the trips before several big promos to dump a boat load more.
What’s in the past?
SINC only got down to .0006 becuase of an active seller. Float was 5 million 2 months ago. Now is probably around 350 million.
ZMRK is a good example. Float is 300 million and is at .0006.
There’s plenty out there. Just have to know how to look.
There is many actually. Just go to look.
Probably some left over, but in theory it should move a bit now. Should be primed for a nice trade
We had $86k left in notes yesterday no?
Twitter pump. Hopefully cleared out all dilution?
I am convinced you are slow…
We just hit new highs since the change of control.
Does it matter?
SICK! MONI
TGRP https://www.cancer.gov/research/participate/clinical-trials/intervention/triapine
Clinical Trials Using Triapine
Clinical trials are research studies that involve people. The clinical trials on this list are studying triapine. All trials on the list are NCI-supported clinical trials, which are sponsored or otherwise financially supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Trials 1-3 of 3
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Location: 23 locations
Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers from the Tissue at the Time of Hysterectomy
This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.
Location: 2 locations
Triapine in Combination with Temozolomide for the Treatment of Patients with Recurrent Glioblastoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.
Location: Northwestern University, Chicago, Illinois
You dont have to take his word for it. The details are all here:
Look at all the universities involved:
https://clinicaltrials.gov/study/NCT02466971
This study has 384 locations
United States
I worry about you…